Deep Responses Reshaping First-Line Standards | Prof. Qiang Dong Discusses the LIBERTAS China Subgroup Results Presented at ASCO GU 2026

Deep Responses Reshaping First-Line Standards | Prof. Qiang Dong Discusses the LIBERTAS China Subgroup Results Presented at ASCO GU 2026

The 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2026) was held in San Francisco, USA, from February 26 to 28, showcasing some of the most innovative scientific advances in the field and exploring future directions in the treatment of genitourinary malignancies. In recent years, research and clinical practice in urologic oncology in China have advanced rapidly. More than 70 studies led by Chinese experts and investigators were presented at the meeting. Among them, the Department of Urology at West China Hospital of Sichuan University contributed 10 studies, including six in prostate cancer, two in upper tract urothelial carcinoma, and two in renal cell carcinoma, highlighting the growing impact of Chinese research on the global stage.
ASCO GU On-Site Report | Prof. Jun Guo: A Year of Strategic Momentum in Genitourinary Oncology—China’s Innovation Breaking New Ground

ASCO GU On-Site Report | Prof. Jun Guo: A Year of Strategic Momentum in Genitourinary Oncology—China’s Innovation Breaking New Ground

The 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU) was held in San Francisco, bringing together leading experts from around the world. As one of the most influential academic meetings in genitourinary oncology, the landmark studies presented each year at ASCO GU often directly shape the evolution of clinical practice globally.
JCO | Frontline BCMA CAR-T Redefines the Treatment Landscape of Multiple Myeloma: 100% MRD Negativity and 94.4% Complete Response Rate

JCO | Frontline BCMA CAR-T Redefines the Treatment Landscape of Multiple Myeloma: 100% MRD Negativity and 94.4% Complete Response Rate

In real-world clinical practice, a considerable proportion of patients with multiple myeloma (MM) are unable to tolerate autologous stem cell transplantation (ASCT) due to advanced age, comorbidities, or poor performance status, creating an urgent need for more effective therapeutic strategies. On February 27, 2026, a research paper entitled Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001) by a Chinese research team was published online in the Journal of Clinical Oncology (IF=43.4). This study provides the first prospective clinical evidence for the field, confirming that the upfront application of B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy as first-line treatment for patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for or not proceeding to transplantation—including those with high-risk disease—achieves an impressive 100% minimal residual disease (MRD) negativity rate and a 94.4% complete response rate (CRR) with a favorable safety profile. This novel therapeutic approach is expected to establish a new paradigm for MM treatment. This article summarizes the key findings of this landmark study for clinical reference.
A Comprehensive Overview of Major International Conferences in Urology and Urologic Oncology in 2026

A Comprehensive Overview of Major International Conferences in Urology and Urologic Oncology in 2026

Everything that has passed is but a prelude. Reflecting on the progress made in urologic oncology in 2025, the field witnessed the release of numerous landmark study results alongside a series of high-level international conferences. These developments have significantly expanded the boundaries of knowledge and provided invaluable platforms for researchers worldwide to exchange ideas and strengthen collaboration.
Annual Review | Prof. Xingkang Jiang and Prof. Yi Liu: Advances in Prostate Biopsy in 2025

Annual Review | Prof. Xingkang Jiang and Prof. Yi Liu: Advances in Prostate Biopsy in 2025

Prostate cancer remains the most prevalent genitourinary malignancy among men worldwide. Early and accurate diagnosis is fundamental to comprehensive disease management, long-term survival improvement, and reduction of the societal burden of disease. As the pathological gold standard for prostate cancer diagnosis, biopsy continues to serve as the central arena for technological innovation and clinical investigation in precision oncology.
Annual Review | Dawn in the “Bladder Preservation Battle”: Prof. Yijun Shen Reviews Key Advances in NMIBC in 2025

Annual Review | Dawn in the “Bladder Preservation Battle”: Prof. Yijun Shen Reviews Key Advances in NMIBC in 2025

The year 2025 marked a pivotal turning point in the management of urothelial carcinoma (UC). Nowhere has this transformation been more striking than in high-risk non–muscle-invasive bladder cancer (NMIBC), where long-standing limitations of bacillus Calmette–Guérin (BCG) therapy are finally being challenged by innovative strategies—most notably immune checkpoint inhibitors (ICIs) and antibody–drug conjugates (ADCs).
Annual Review | Precision Stratification and Synergistic Combinations: Prof. Xinan Sheng Reviews Key Advances in Renal Cell Carcinoma in 2025

Annual Review | Precision Stratification and Synergistic Combinations: Prof. Xinan Sheng Reviews Key Advances in Renal Cell Carcinoma in 2025

In 2025, the field of renal cell carcinoma (RCC) advanced decisively along the dual pathways of precision and combination therapy. Landmark developments reshaped clinical practice across disease stages: perioperative targeted–immunotherapy combinations that altered surgical paradigms for locally advanced disease; long-term survival data confirming the durability of first-line immunotherapy-based regimens; innovative later-line strategies overcoming therapeutic resistance; and biomarker-driven approaches enabling molecularly guided treatment for rare non–clear cell subtypes.
Breakthrough in Advanced Renal Cancer: Prof. Hailiang Zhang and Team Propose a Precision Surgery Strategy

Breakthrough in Advanced Renal Cancer: Prof. Hailiang Zhang and Team Propose a Precision Surgery Strategy

In recent years, the combination of targeted therapy and immunotherapy has substantially improved systemic outcomes for patients with advanced clear cell renal cell carcinoma (ccRCC). However, whether these regimens can be effectively deployed in the preoperative setting as conversion therapy—enhancing surgical resectability and nephron preservation—has lacked prospective real-world validation. Furthermore, their impact on the tumor immune microenvironment remains incompletely understood.